To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
GTCR to invest $200m in pharma platform
Fresh from its $900m exit of Ovation Pharmaceuticals, US buyout veteran GTCR has established a buy-and-build platform for specialty pharmaceutical companies and products.
